FDA approvals plus AI-and-energy phase shifts
Global active cure-related trials now total 21,166, with 65 new Cure research updates and 62 new Wire signals in the last 24 hours—an unusually steady flow of both biology and enabling tech. On the cure front, the FDA approved LISRAYA (brepocitinib) for adults with dermatomyositis, and Takeda received FDA approval of MIMRYLO (rusfertide) for erythrocytosis in polycythemia vera, while ZIIHERA-containing regimens posted statistically significant overall survival benefits in HER2+ gastroesophageal cancer interim Phase 3 results. Meanwhile, the Wire’s top signals read like a broader phase transition: data centers are pitching nuclear power to overcome grid limits for AI workloads, and security vendors are rebuilding AI DLP around contextual understanding rather than signatures. These moves matter because faster, better cure development depends not just on clinical results, but on the compute, infrastructure, and safety systems that scale deployment—without letting permitting, compliance, or trust gaps close the window. The window is still open.
Data centers are pitching nuclear power as a supply-side solution to AI-driven energy demand outrunning grid limits.
Cures advance faster when compute and infrastructure scale reliably, but energy and regulatory constraints can slow deployment while approvals and clinical momentum accelerate disease-specific wins.
Watch for how nuclear-for-data-center plans clear permitting and compliance bottlenecks while continuing to track FDA oncology and rare-disease approvals and their Phase 3 follow-through pressure.